CANCER RESEARCH

# TABLE OF CONTENTS

## IN THE SPOTLIGHT



## CANCER BIOLOGY



## CANCER IMMUNOLOGY



## CANCER METABOLISM AND MOLECULAR MECHANISMS

# TABLE OF CONTENTS

## THERAPEUTIC DEVELOPMENT AND CHEMICAL BIOLOGY



## TRANSLATIONAL CANCER BIOLOGY



## EDITOR'S NOTES

# TABLE OF CONTENTS

## ABOUT THE COVER



Mutant KRAS drives pancreatic ductal adenocarcinoma (PDAC) initiation and progression. The receptor tyrosine kinase FGFR2 supports mutant KRAS signaling in the early phases of pancreatic tumorigenesis and the inactivation of FGFR2 intercepts disease development. The cover image depicts a murine precancerous lesion expressing FGFR2 (green), acquiring invasive features (p53 accumulation in orange and increased CDKN2A/ARF transcriptional expression in cyan), and progressing to PDAC. For details, see article by Tonelli and colleagues on page 1960.

**doi:** 10.1158/0008-5472.CAN-85-11-CVR

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR's established policies for authors, please go to https:/aacrjournals.org/pages/editorial-policies#coi.